| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
International University Bremen, School of Engineering and Science, Bremen, Germany
To the Editor:
The recent study by Verkasalo et al. (1) describes the correlation between sleep duration and breast cancer incidence in a prospective cohort study. The results are in principal agreement with the theory that longer sleep is associated with higher melatonin levels, which, in turn, are able to suppress cancer growth. The significance of the findings by Verkasalo et al. is central for the question why cancer incidence is higher in industrialized nations. Surprisingly and disappointingly, though, the authors fail to acknowledge the input by Dr. Erren who not only authored key papers in this regard (2, 3) but who also organized, in 2002, an international conference on this topic in Cologne, Germany. Actually, at least one of the authors of the paper (1) attended the meeting. In his 2002 paper, Erren wrote: "There may be merit, therefore, in considering a possible alternative index of melatonin levels that does not require measurement of biomarkers. The available clinical and experimental laboratory evidence suggests that this could be individuals' cumulative time at sleep."
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |